Compare CCEL & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCEL | TXMD |
|---|---|---|
| Founded | 1989 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8M | 24.3M |
| IPO Year | 2022 | 2012 |
| Metric | CCEL | TXMD |
|---|---|---|
| Price | $3.55 | $2.00 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.8K | ★ 21.5K |
| Earning Date | 04-14-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.26% | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | 0.01 | 0.01 |
| Revenue | ★ $25,384,279.00 | $1,761,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $341.00 | ★ N/A |
| Revenue Growth | 9.76 | ★ 35.25 |
| 52 Week Low | $2.72 | $0.98 |
| 52 Week High | $5.52 | $2.95 |
| Indicator | CCEL | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 46.22 | 45.90 |
| Support Level | $3.18 | $1.93 |
| Resistance Level | $4.22 | $2.05 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 0.01 | 36.79 |
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.